Title: Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
Journal: British journal of pharmacology 20110401
Title: Cannon MV et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.Eur J Heart Fail. 2015 Mar;17(3):273-82.
Title: van der Hoorn J et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.Br J Pharmacol. 2011 Apr;162(7):1553-63.